Trials / Terminated
TerminatedNCT00362700
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (planned)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and antiviral activity of Clevudine, when retreated to patients previously treated with Clevudine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine |
Timeline
- Start date
- 2003-07-01
- Completion
- 2005-10-01
- First posted
- 2006-08-10
- Last updated
- 2017-02-01
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00362700. Inclusion in this directory is not an endorsement.